Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
LogicBio Therapeutics Inc is a biotechnology business based in the US. LogicBio Therapeutics shares (LOGC) are listed on the NASDAQ and all prices are listed in US Dollars. LogicBio Therapeutics employs 62 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.40 |
|---|---|
| 52-week range | $0.34 - $5.15 |
| 50-day moving average | $0.48 |
| 200-day moving average | $1.94 |
| Wall St. target price | $6.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.12 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.3965 from 2022-07-01
| 1 week (2022-06-24) | -7.79% |
|---|---|
| 1 month (2022-06-03) | -22.25% |
| 3 months (2022-04-01) | -44.93% |
| 6 months (2022-01-03) | -84.08% |
| 1 year (2021-07-02) | -90.82% |
|---|---|
| 2 years (2020-07-02) | -95.23% |
| 3 years (2019-07-03) | 11.32 |
| 5 years (2017-06-29) | N/A |
| Revenue TTM | $7.8 million |
|---|---|
| Gross profit TTM | $-22,759,000 |
| Return on assets TTM | -35.19% |
| Return on equity TTM | -92.02% |
| Profit margin | 0% |
| Book value | $0.76 |
| Market capitalisation | $14.2 million |
TTM: trailing 12 months
We're not expecting LogicBio Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, LogicBio Therapeutics's shares have ranged in value from as little as $0.34 up to $5.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LogicBio Therapeutics's is 1.4863. This would suggest that LogicBio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
LogicBio Therapeutics, Inc. , a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.